{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rosuvastatin+10+mg+tablet&page=2",
    "query": {
      "intervention": "rosuvastatin 10 mg tablet",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rosuvastatin+10+mg+tablet&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rosuvastatin+10+mg+tablet&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T06:34:37.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04764851",
      "title": "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-Interactions"
      ],
      "interventions": [
        {
          "name": "ecopipam HCl ~2mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 Probe Cocktail",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort 2 Probe Cocktail",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort 3 Probe Cocktail",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Emalex Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-18",
      "completion_date": "2021-05-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04764851"
    },
    {
      "nct_id": "NCT05334108",
      "title": "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Interaction"
      ],
      "interventions": [
        {
          "name": "Ecopipam",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 Probe Substrate Cocktail",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort 2 Probe Substrate",
          "type": "DRUG"
        },
        {
          "name": "Cohort 3 Probe Substrate Cocktail",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Emalex Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-04-26",
      "completion_date": "2022-08-26",
      "has_results": false,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334108"
    },
    {
      "nct_id": "NCT01489943",
      "title": "A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "GSK1605786 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 15 mg",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-09-19",
      "completion_date": "2011-11-10",
      "has_results": false,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489943"
    },
    {
      "nct_id": "NCT00487136",
      "title": "Interaction Between ABT-335, Rosuvastatin and Warfarin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "warfarin plus ABT-335 plus rosuvastatin 5 mg",
          "type": "DRUG"
        },
        {
          "name": "warfarin plus ABT-335 plus rosuvastatin 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2007-06",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2012-09-28",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487136"
    },
    {
      "nct_id": "NCT07372625",
      "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TP53 Y220C Mutation",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "metformin hydrochloride 500 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "rosuvastatin 10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "repaglinide 0.5 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "midazolam hydrochloride syrup",
          "type": "DRUG"
        },
        {
          "name": "rezatapopt",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-02-04",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07372625"
    },
    {
      "nct_id": "NCT06821698",
      "title": "To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healty Volunteers"
      ],
      "interventions": [
        {
          "name": "KP-001",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin calcium10mg",
          "type": "DRUG"
        },
        {
          "name": "Caffeine citrate",
          "type": "DRUG"
        },
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaken Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2025-02-13",
      "completion_date": "2025-05-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06821698"
    },
    {
      "nct_id": "NCT03772262",
      "title": "Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Interaction Drug Food"
      ],
      "interventions": [
        {
          "name": "goldenseal",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Furosemide",
          "type": "DRUG"
        },
        {
          "name": "Midazolam oral solution",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Washington State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2018-04-05",
      "completion_date": "2019-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-28",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03772262"
    },
    {
      "nct_id": "NCT03864042",
      "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "losartan",
          "type": "DRUG"
        },
        {
          "name": "dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "caffeine",
          "type": "DRUG"
        },
        {
          "name": "omeprazole",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "bupropion immediate release (IR)",
          "type": "DRUG"
        },
        {
          "name": "encorafenib",
          "type": "DRUG"
        },
        {
          "name": "binimetinib",
          "type": "DRUG"
        },
        {
          "name": "modafinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2018-01-02",
      "completion_date": "2023-05-29",
      "has_results": true,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 11,
      "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hopkins",
          "state": "Minnesota"
        },
        {
          "city": "Maple Grove",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03864042"
    },
    {
      "nct_id": "NCT02082665",
      "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg syrup",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib 75 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-02-19",
      "completion_date": "2016-08-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-24",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082665"
    },
    {
      "nct_id": "NCT01730040",
      "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2012-10",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-08-31",
      "last_synced_at": "2026-10-01T06:34:37.227Z",
      "location_count": 56,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730040"
    }
  ]
}